Close Menu

BC Cancer Foundation

Epic Sciences will donate its No Cell Left Behind platform to the clinical trial, which will enroll about 1,000 patients over three years.

The funding will support the British Columbia Cancer Agency's effort to use genome sequencing to develop personalized treatment strategies for cancer patients.

Among 100 adults and six children recruited between June 2012 and August 2014, most were successfully sequenced and a majority of those had actionable results.

Researchers leading the POG trial are hoping this year to sequence the whole genomes of 300 cancer patients in an effort to find the best treatment options for them.

The goal is to analyze a variety of genomic techniques, including sequencing, to develop a test that will determine whether AML patients should receive chemotherapy or stem cell transplantation.

The Genome British Columbia program will kick off with funding totaling around $9 million for three personalized medicine studies.

A man has confessed to the rape and murder of developmental biologist Suzanne Eaton, according to the New York Times.

The Irish Times reports that US lawmakers and law enforcement agencies are concerned about ties between the US and Chinese genomics firms.

Parents of children with spinal muscular atrophy tell the Washington Post they are pushing to get insurance coverage of Novartis's Zolgensma.

In PNAS this week: gene mutations in individuals with syndromic craniosynostosis, putative colorectal cancer drivers, and more.